Roles of eukaryotic initiation factor 5A2 in human cancer

International Journal of Biological Sciences

Volumn 9, Issue 10, 2013, Pages 1013-1020

  Wang, Feng Wei ^a   Guan, Xin Yuan ^b   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Epithelial mesenchymal transition; Eukaryotic initiation factor 5A2; Metastasis

Indexed keywords

EIF 5A2; EIF-5A2; INITIATION FACTOR; TUMOR MARKER; TUMOR PROTEIN;

CELL FRACTIONATION; EPITHELIAL MESENCHYMAL TRANSITION; EUKARYOTIC INITIATION FACTOR 5A2; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; METASTASIS.; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; EUKARYOTIC INITIATION FACTOR 5A2; METASTASIS.;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE INITIATION FACTORS; SUBCELLULAR FRACTIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904237079     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7191     Document Type: Review

References (73)

1. Guan XY, Sham JS, Tang TC, et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 2001; 61:3806-3809.
2. Park MH, Nishimura K, Zanelli CF, et al. Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 2010; 38:491-500.
3. Caraglia M, Park MH, Wolff EC, et al. eIF5A isoforms and cancer: two brothers for two functions?. Amino Acids 2013; 44:103-109.
4. Park MH, Wolff EC, Folk JE. Hypusine: its post-translational formation in eukaryotic initiation factor 5A and its potential role in cellular regulation. Biofactors 1993; 4:95-104.
5. Chen KY, Liu AY. Biochemistry and function of hypusine formation on eukaryotic initiation factor 5A. Biol Signals 1997; 6:105-109.
6. Abbruzzese A. Developmental pattern for deoxyhypusine hydroxylase in rat brain. J Neurochem. 1988;50:695-699
7. Abbruzzese A, Park MH, Beninati S, et al. Inhibition of deoxyhypusine hydroxylase by polyamines and by a deoxyhypusine peptide. Biochim Biophys Acta. 1989;997:248-255.
8. Caraglia M, Budillon A, Vitale G, et al. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur. J. Biochem. 2000; 267:3919-3936.
9. Saini P, Eyler DE, Green R, et al. Hypusine-containing protein eIF5A promotes translation elongation. Nature 2009; 459:118-121.
10. Jenkins ZA, Haag PG, Johansson HE. Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics 2001; 71:101-109.
11. Clement PM, Henderson CA, Jenkins ZA, et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur J Biochem. 2003; 270:4254-4263.
12. Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010; 11:113-127.
13. Beninati S, Nicolini L, Jakus J, et al. Identification of a substrate site for transglutaminases on the human protein synthesis initiation factor 5A. Biochem J. 1995; 305:725-728.
14. Caraglia M, Passeggio A, Beninati S, et al. Interferon a2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. Biochem J. 1997; 324:737-741.
15. Beninati S, Gentile V, Caraglia M, et al. Tissue transglutaminase expression a¡ects hypusine metabolism in BALB/c 3T3 cells. FEBS Letters 1998; 437:34-38
16. Caraglia M, Marra M, Giuberti G, et al. The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-a and EGF in human cancer cells. J Biochem. 2003;133:757-765.
17. Lalande M, Hanauske-Abel HM. A new compound which reversibly arrests T lymphocyte cell cycle near the G1/S boundary. Exp Cell Res. 1990; 188:117-121.
18. Tong Y, Park I, Hong BS et al. Crystal structure of human eIF5A1: insight into functional similarity of human eIF5A1 and eIF5A2. Proteins 2009; 75:1040-1045.
19. Zuk D, Jacobson A. A single amino acid substitution in yeast eIF-5A results in mRNA stabilization. EMBO J. 1998; 17:2914-2925.
20. Ishfaq M, Maeta K, Maeda S et al. The role of acetylation in the subcellular localization of an oncogenic isoform of translation factor eIF5A. Biosci Biotechnol Biochem. 2012; 76:2165-2167.
21. Ishfaq M, Maeta K, Maeda S et al. Acetylation regulates subcellular localization of eukaryotic translation initiation factor 5A (eIF5A). FEBS Lett. 2012; 586:3236-3241.
22. Klier H, Csonga R, Joao HC et al. Isolation and structural characterization of different isoforms of the hypusine-containing protein eIF-5A from HeLa cells. Biochemistry 1995; 34:14693-14702.
23. Lipowsky G, Bischoff FR, Schwarzmaier P et al. Exportin 4: a mediator of a novel nuclear export pathway in higher eukaryotes. EMBO J. 2000; 19:4362-4371.
24. Zender L, Xue W, Zuber J et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135:852-864.
25. Griffin CA, Morsberger L, Hawkins AL et al. Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations. Cytogenet Genome Res. 2007; 118:148-156.
26. Yen CC, Chen YJ, Pan CC et al. Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is amplified in early carcinogenesis but down-regulated as disease progressed. World J Gastroenterol. 2005; 11:1267-1272.
27. Pack SD, Karkera JD, Zhuang Z et al. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer 1999; 25:160-168.
28. Sattler HP, Lensch R, Rohde V et al. Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate 2000; 45:207-215.
29. Viegas-Pequignot E, Flury-Herard A, De Cremoux H et al. Recurrent chromosome aberrations in human lung squamous cell carcinomas. Cancer Genet Cytogenet. 1990; 49:37-49.
30. Shen H, Zhu Y, Wu YJ et al. Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genet Cytogenet. 2008; 181:100-107.
31. Guan XY, Fu SB, Xia JC et al. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet. 2000; 123:27-34.
32. Takada H, Imoto I, Tsuda H et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci. 2005; 96:100-110.
33. Guan XY, Fung JM, Ma NF et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 2004; 64:4197-4200.
34. He QJ, Zeng WF, Sham JS et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet. 2003; 144:112-118.
35. Tang DJ, Dong SS, Ma NF et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 2010; 51:1255-1263.
36. Luo JH, Hua WF, Rao HL et al. Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. Cancer Sci. 2009; 100:896-902.
37. Forozan F, Mahlamaki EH, Monni O et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res. 2000; 60:4519-4525.
38. Fang Y, Guan X, Guo Y et al. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer 2001; 30:254-260.
39. Clement PM, Johansson HE, Wolff EC et al. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J. 2006; 273:1102-1114.
40. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
41. Caraglia M, Marra M, Giuberti G, et al. The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. Amino Acids. 2001; 20:91-104.
42. Wolff EC, Kang KR, Kim YS et al. Posttranslational synthesis of hypusine: evolutionary progression and specificity of the hypusine modification. Amino Acids 2007; 33:341-350.
43. Nishimura K, Murozumi K, Shirahata A et al. Independent roles of eIF5A and polyamines in cell proliferation. Biochem J. 2005; 385:779-785.
44. Jasiulionis MG, Luchessi AD, Moreira AG et al. Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem Funct. 2007; 25:109-114.
45. Xie D, Ma NF, Pan ZZ et al. Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum Pathol. 2008; 39:80-86.
46. Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003; 33:49-54.
47. Lee NP, Tsang FH, Shek FH et al. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer 2010; 127:968-976.
48. Marchet A, Mocellin S, Belluco C et al. Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol. 2007; 14:1058-1064.
49. Zhu W, Cai MY, Tong ZT et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut 2012; 61:562-575
50. Chen M, Huang JD, Deng HK et al. Overexpression of eIF-5A2 in mice causes accelerated organismal aging by increasing chromosome instability. BMC Cancer 2011; 11:199.
51. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci. 1998; 3:250-268.
52. Bishop JM. Retroviruses and cancer genes. Adv Cancer Res. 1982; 37:1-32.
53. Bouchard C, Staller P, Eilers M. Control of cell proliferation by Myc. Trends Cell Biol. 1998; 8:202-206.
54. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999; 19:1-11.
55. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-3016.
56. Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-128.
57. Shi Y, Glynn JM, Guilbert LJ et al. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992; 257:212-214.
58. Campisi J. Aging and cancer: the double-edged sword of replicative senescence. J Am Geriatr Soc. 1997; 45:482-488.
59. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-740.
60. Kang HA, Schwelberger HG, Hershey JW. The two genes encoding protein synthesis initiation factor eIF-5A in Saccharomyces cerevisiae are members of a duplicated gene cluster. Mol Gen Genet. 1992; 233:487-490.
61. Schwelberger HG, Kang HA, Hershey JW. Translation initiation factor eIF-5A expressed from either of two yeast genes or from human cDNA. Functional identity under aerobic and anaerobic conditions. J Biol Chem. 1993; 268:14018-14025.
62. Vu VV, Emerson JP, Martinho M et al. Human deoxyhypusine hydroxylase, an enzyme involved in regulating cell growth, activates O2 with a nonheme diiron center. Proc Natl Acad Sci. 2009; 106:14814-14819.
63. Yang GF, Xie D, Liu JH et al. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecol Oncol. 2009; 112:314-318.
64. Chen W, Luo JH, Hua WF et al. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol Biomarkers Prev. 2009; 18:400-408.
65. He LR, Zhao HY, Li BK et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int J Cancer 2011; 129:143-150.
66. Shek FH, Fatima S, Lee NP. Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma. Int J Hepatol. 2012; 2012:760-928.
67. Lee Y, Kim HK, Park HE et al. Effect of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on endothelial cell growth, differentiation and apoptosis. Mol Cell Biochem. 2002; 237:69-76.
68. Taylor CA, Sun Z, Cliche DO et al. Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. Exp Cell Res. 2007; 313:437-449.
69. Sun Z, Cheng Z, Taylor CA et al. Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway. J Cell Physiol. 2010; 223:798-809.
70. Moore CC, Martin EN, Lee G et al. Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury. J Infect Dis. 2008; 198:1407-1414.
71. Li AL, Li HY, Jin BF et al. A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem. 2004; 279:49251-49258.
72. Hoque M, Hanauske-Abel HM, Palumbo P et al. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 2009; 6:90.
73. Balabanov S, Gontarewicz A, Ziegler P, et al. Hypusination of eukaryotic initiation factor 5A (eIF5A):a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007; 109:1701-1711.